Could a common heart drug help protect newborn brains?
NCT ID NCT06810284
First seen Feb 20, 2026 · Last updated Jun 13, 2026 · Updated 19 times
Summary
This study looks at how the drug sildenafil is processed in the bodies of full-term newborns who have suffered brain injury from lack of oxygen at birth. All babies will receive standard cooling therapy. The goal is to find the right dose for a future larger trial that will test if adding sildenafil to cooling can prevent brain damage. 24 babies will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXIC-ISCHEMIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre
Paris, 75005, France
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.